research use only
Cat.No.S3160
| Related Targets | Adrenergic Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR |
|---|---|
| Other Estrogen/progestogen Receptor Inhibitors | Elacestrant (RAD1901) Dihydrochloride MPP dihydrochloride Cholesterol Endoxifen HCl G15 Chrysin Licochalcone A AZD9496 PHTPP Liquiritigenin |
|
In vitro |
DMSO
: 77 mg/mL
(200.25 mM)
Water : 77 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 384.51 | Formula | C24H32O4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 297-76-7 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | 8080 CB,Ethynodiol acetate | Smiles | CC(=O)OC1CCC2C3CCC4(C(C3CCC2=C1)CCC4(C#C)OC(=O)C)C | ||
| Targets/IC50/Ki |
Progesterone receptor
|
|---|---|
| In vitro |
Nordihydroguaiaretic acid (NDGA) (< 1.5 μM) decreases the percentage of sister chronnatid exchanges (SCEs) in human lymphocyte culture treated with ethynodiol diacetate (150 μg/mL). Since the NDGA treatment, in the presence of S9 mix, reduce the genotoxic damage by ethynodiol diacetate, the reduction may be due to the inhibition of cytochrome P450s which prevents the metabolic activation of ethynodiol diacetate or NDGA may act as a free radical scavenger. Ethynodiol diacetate (150 μg/mL) increases sister chromatid exchanges (SCEs) and chromosomal aberrations (CAs) frequencies and inhibits lymphocyte proliferation in the presence of S9 mix in human lymphocyte. |
| In vivo |
Ethynodiol diacetate (6 mg/kg b.w. daily) significantly increases the amounts of excreted 3alpha-hydroxy-5alpha-pregnan-20-one and A-homo-3-oxa-5alpha-pregnane-4,20-dione in urine in female rats. Significant increase in the weights of pituitary, liver and kidneys are noted in rats treated with ethynodiol diacetate (6 mg/kg b.w. daily). Norgestrel (75 μg/day) and ethynodiol diacetate (150 μg/day), co-administered with ethinyl estradiol (7.5 μg/day), lowers the plasma concentrations of HDL cholesterol in cynomolgus monkeys. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.